IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 333 filers reported holding IONIS PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 1.69 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $48,974,357 | -7.0% | 1,296,647 | +8.9% | 0.01% | -14.3% |
| Q3 2022 | $52,666,917 | +27.2% | 1,190,751 | +6.5% | 0.01% | +27.3% |
| Q2 2022 | $41,400,984 | +42.3% | 1,118,341 | +42.4% | 0.01% | +83.3% |
| Q1 2022 | $29,097,179 | +15.0% | 785,561 | -5.5% | 0.01% | +20.0% |
| Q4 2021 | $25,294,000 | -34.2% | 831,219 | -27.5% | 0.01% | -44.4% |
| Q3 2021 | $38,468,000 | +7.6% | 1,146,918 | +28.0% | 0.01% | +12.5% |
| Q2 2021 | $35,753,000 | -1.5% | 896,289 | +11.0% | 0.01% | 0.0% |
| Q1 2021 | $36,305,000 | -15.6% | 807,488 | +6.2% | 0.01% | -20.0% |
| Q4 2020 | $42,994,000 | +4.9% | 760,425 | -12.0% | 0.01% | -9.1% |
| Q3 2020 | $40,983,000 | -21.6% | 863,716 | -2.5% | 0.01% | -26.7% |
| Q2 2020 | $52,247,000 | +3.7% | 886,145 | -16.8% | 0.02% | -16.7% |
| Q1 2020 | $50,383,000 | -31.0% | 1,065,637 | -11.9% | 0.02% | -10.0% |
| Q4 2019 | $73,035,000 | -12.6% | 1,208,987 | -13.4% | 0.02% | -23.1% |
| Q3 2019 | $83,599,000 | -3.6% | 1,395,397 | +3.5% | 0.03% | -3.7% |
| Q2 2019 | $86,685,000 | -20.5% | 1,348,762 | +0.4% | 0.03% | -22.9% |
| Q1 2019 | $108,994,000 | +100.1% | 1,342,776 | +33.3% | 0.04% | +75.0% |
| Q4 2018 | $54,463,000 | -12.2% | 1,007,444 | -16.3% | 0.02% | 0.0% |
| Q3 2018 | $62,055,000 | +85.4% | 1,203,089 | +49.8% | 0.02% | +81.8% |
| Q2 2018 | $33,475,000 | -5.5% | 803,338 | 0.0% | 0.01% | -15.4% |
| Q1 2018 | $35,410,000 | -11.8% | 803,338 | +0.6% | 0.01% | -7.1% |
| Q4 2017 | $40,158,000 | -19.8% | 798,371 | -19.2% | 0.01% | -26.3% |
| Q3 2017 | $50,098,000 | +45.2% | 988,126 | +45.7% | 0.02% | +35.7% |
| Q2 2017 | $34,496,000 | +20.0% | 678,126 | -5.2% | 0.01% | +16.7% |
| Q1 2017 | $28,757,000 | -43.6% | 715,356 | -32.9% | 0.01% | -45.5% |
| Q4 2016 | $50,976,000 | +67.1% | 1,065,766 | +22.2% | 0.02% | +57.1% |
| Q3 2016 | $30,508,000 | +39.8% | 871,794 | -6.9% | 0.01% | +40.0% |
| Q2 2016 | $21,815,000 | -47.2% | 936,681 | -8.1% | 0.01% | -50.0% |
| Q1 2016 | $41,279,000 | -34.6% | 1,019,236 | 0.0% | 0.02% | -35.5% |
| Q4 2015 | $63,121,000 | – | 1,019,236 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bellevue Group AG | 9,930,245 | $396,117,000 | 3.87% |
| Sicart Associates LLC | 368,409 | $14,696,000 | 3.50% |
| Camber Capital Management LP | 2,000,000 | $79,780,000 | 2.69% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 181,781 | $7,251,000 | 1.91% |
| SECTOR GAMMA AS | 263,488 | $10,511,000 | 1.86% |
| Parkman Healthcare Partners LLC | 136,380 | $5,440,000 | 1.19% |
| Eversept Partners, LP | 442,000 | $17,631,380 | 1.18% |
| Affinity Asset Advisors, LLC | 75,000 | $2,992,000 | 1.07% |
| TANAKA CAPITAL MANAGEMENT INC | 16,661 | $665,000 | 0.90% |
| Sonora Investment Management, LLC | 168,665 | $6,728,000 | 0.88% |